This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
Four days ago I wrote that “the regulatory war ended August 6. The financing war ended today. The commercial one starts in about 60 days.” The fiscal Q1 report today confirms all three. It also quietly corrects a number I have carried through eight consecutive posts, and readers deserve to have it flagged loudly rather than buried in a footnote.
The stock closed at $14.97, up 9.5% from Monday’s $13.67 — a fourth consecutive session of gains and now roughly triple the $5.41 print on the eve of the July 30 advisory committee vote.
The Receipts
The going-concern paragraph is gone — in substance, on paper. The 10-Q states it plainly: “The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.” Cash and short-term investments were $195.3 million at June 30 (down from $268.9M at March 31), plus the raise puts pro-forma liquidity above $335M, funding operations “for greater than twelve months.” The implication: the specific risk I named on August 7 as “the near-term risk, not the science” has been retired in the filing that matters. PwC’s explanatory paragraph attaches to the audited FY2026 statements and won’t formally disappear until the next audit, but the substance behind it is answered.
A real Chief Commercial Officer, effective August 18. Michelle DiNapoli joins from a seven-year run at Deciphera Pharmaceuticals, where she built the U.S. sales force and scaled a single-product launch into a multi-product commercial organization, preceded by 16 years at Genentech across breast, lung, colorectal and cancer immunotherapy. Why it matters: on August 7 I wrote that the launch deck “reads like a company that prepared properly for a launch it wasn’t certain it would get,” but the April restructuring eliminated ~55% of the workforce, “impacting the entirety of the Company’s commercial team.” Hiring a launch operator with a Deciphera single-product-to-multi-product track record is the most credible signal yet that the rebuild is being run by someone who has done this exact job. This is the hire the thesis needed.
The burn is real but the shape has changed. Net loss of $69.8M for the quarter vs. $86.7M a year ago. R&D fell to $49.3M from $57.8M; SG&A fell to $19.0M from $32.6M, driven by a $10.2M cut in external sales and marketing plus $3.4M in personnel. Inside R&D, the mix inverted: IGNYTE spend collapsed to $0.7M (from $3.5M), while IGNYTE-3 rose to $8.0M (from $4.9M) and RP2 rose to $8.8M (from $3.9M) as REVEAL enrollment expanded outside the U.S. The implication: this is a company that has stopped paying for the registrational trial and started paying for the confirmatory one and the next asset. That’s the correct shape — but SG&A of $19.0M is a pre-launch number, and it goes up from here.
The Hercules maturity extended to October 1, 2029. The Third Amendment carried a clause: FDA approval before October 1, 2027 extends amortization and maturity by two years. Approval landed, so the $84.2M principal balloon moves to 2029, with interest-only payments through September 2029 at the greater of 8.50% or Prime + 1.75%, plus 1.50% PIK. Why it matters: no principal amortization before launch revenue arrives is a materially better debt profile than it looked three months ago. Watch the covenant that kicks in when the balance hits $100M: trailing three-month product revenue, or a $1.2 billion market cap with 50% cash coverage, or 85% cash coverage. At a ~$1.4B market cap the second door is currently open, but it’s a stock-price-dependent covenant, which is not the kind you want to lean on.
Ridgeback cut from 8.7% to 3.5%. A 13G-A filed today discloses Ridgeback Capital held 7,310,656 shares (8.7%) as of the June 30 event date but 2,912,373 shares (3.5%) as of August 13. That’s roughly 4.4 million shares distributed into the approval rally. The tea leaf: this is not the Baker Bros resale shelf — it’s a separate specialist holder taking real chips off the table into strength. Sensible risk management after a triple, and exactly the behavior I’ve described as “housekeeping” for anyone holding from the May lows. But it also means the supply I flagged on July 24 is not hypothetical; some of it has already hit the tape, and the 25,103,489-share (25.94%) Baker Bros shelf remains live above it.
The Correction That Matters
Here is the line in today’s press release that changes something real:
IGNYTE-3’s “primary endpoint, expected to readout in 2030, is overall survival.”
I have written “interim OS in 2H 2027” in every REPL update since February. That number came from the company’s own prior framing and I carried it forward without re-verifying it against the post-approval disclosures. Today’s release states the primary OS analysis reads out in 2030. The 10-Q describes IGNYTE-3 as the FDA postmarketing requirement — ~400 patients, randomized 1:1 against physician’s choice, OS primary — and says enrollment continues, but attaches no 2027 interim.
Why this matters, in plain terms. Accelerated approval is a lease with a renewal clause; I’ve used that phrase three times now. What changed today is the length of the lease. If the verification readout is 2030 rather than 2027, then TUDRIQEV has roughly four years of unchallenged commercial runway rather than one. That is good for the equity in the near term — there is no 2027 binary sitting on top of the launch, and four years of revenue is enough time to build a real franchise and fund the rest of the pipeline.
It is also worse in one specific way. Contribution of effect — how much of the 24.2% ORR in the n=91 efficacy-evaluable population is the virus versus re-sensitization to nivolumab — is the one scientific question a single-arm trial structurally cannot answer. That question now stays open for four more years. Anyone underwriting this equity is underwriting a drug whose randomized proof of benefit is further away than the market has been modeling. And when it does arrive, a miss doesn’t mean “no approval” — it means withdrawal of a marketed product with a sales force and a supply chain built on top of it.
How should a reader weigh the odds? Cautiously optimistic, with the caveat that OS in a randomized trial is a genuinely harder bar than ORR in a single-arm cohort. The supporting evidence is the strongest version of the case: 32.9-month median OS in the broader n=140 dataset against a historical median of roughly 8–10 months in anti-PD-1-failed melanoma, 47.8% alive at three years, and the tiebreaker I decoded after the AdCom — 66.0% (35/53) of non-injected visceral lesions shrinking more than 30%, which is the systemic-effect signal Amgen’s Imlygic could never convincingly produce. Against that, IGNYTE-3’s comparator is physician’s choice including Opdualag and PD-1 rechallenge, and randomized trials have a long history of compressing effect sizes that looked enormous in single-arm cohorts. The effect size suggests a reasonable probability of success; it does not guarantee it, and a 2030 readout means we won’t know for a very long time.
The Litigation Ledger
Worth noting because it’s cheaper to track now than to be surprised by later. The securities class action (Jboor v. Replimune, D. Mass.) has a second amended complaint addressing the April CRL, with the Company’s response due August 17, 2026 — Monday. A second complaint (Toor) was filed August 6, the day of approval. Three consolidated derivative actions are stayed. The genuinely good news: on June 24, 2026 the SEC informed the Company it had concluded its investigation and is not recommending enforcement action. The implication: the most dangerous of the legal overhangs is closed. The private litigation is expensive and distracting but is a known quantity for a stock that fell from the $20s to $4.76 on two CRLs.
Decoding the +9.5%
Three things, and they compound.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.